InsidersTradesSigma
Total declarations
Companies
▲ Purchases (21 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
21
Disclosed sells
0
T+90 hit rate
13%
T+90 mean return
-24.3%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Duggan Robert W, Chief Executive Officer. Officer active across 3 companies, notably Summit Therapeutics Inc.. Cumulatively, 38 filings have been logged. Split: 21 buys · 0 sell. Total volume traded: €638.8m. Activity tracked since 12 May 2021. The latest transaction was filed on 4 June 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Duggan Robert W
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations38 total
100,000 shares@ US$14.600.012% mcap1.3% of flowCommon StockSEC:0001055919-26-000005:0
Canonical exit: 2 Sept 2026 (T+90)
660,233 shares@ US$19.690.65% mcap10.4% of flowCommon StockSEC:0001437749-26-017478:0
Canonical exit: 9 Aug 2026 (T+90)
13,980,789 shares@ US$18.7429.4% of flowCommon StockSEC:0001055919-25-000003:0
34,659 shares@ US$14.660.2% of flowCommon StockSEC:0001437749-25-028988:0
Canonical exit: 9 Dec 2025 (T+90)
333,394 shares@ US$17.680.9% of flowCommon StockSEC:0001599298-25-000142:0
Canonical exit: 9 Dec 2025 (T+90)
74,545 shares@ US$2.640.0% of flowCommon StockSEC:0001599298-25-000106:0
3,985,055 shares@ US$1.581.1% of flowCommon StockSEC:0001599298-25-000058:0
5,187,824 shares@ US$11.0022.7% of flowCommon StockSEC:0000950170-24-138177:0
55,256 shares@ US$17.180.4% of flowCommon StockSEC:0001437749-24-037766:0
Canonical exit: 13 Mar 2025 (T+90)
45,404 shares@ US$17.130.3% of flowCommon StockSEC:0000950170-24-136901:0
Canonical exit: 12 Mar 2025 (T+90)
6,054 shares@ US$16.740.0% of flowCommon StockSEC:0001437749-24-037509:0
Canonical exit: 11 Mar 2025 (T+90)
3,325,991 shares@ US$22.7012.8% of flowCommon StockSEC:0001599298-24-000139:0
5,187,824 sharesCommon StockSEC:0001437749-24-022358:0
17,999 shares@ US$9.150.1% of flowCommon StockSEC:0001437749-23-034484:0
Canonical exit: 11 Mar 2024 (T+90)
90,118 shares@ US$9.360.3% of flowCommon StockSEC:0001437749-23-034371:0
Canonical exit: 10 Mar 2024 (T+90)
116,656 shares@ US$9.540.4% of flowCommon StockSEC:0001437749-23-034250:0
Canonical exit: 7 Mar 2024 (T+90)
74,852 shares@ US$9.190.3% of flowCommon StockSEC:0001437749-23-034104:0
Canonical exit: 6 Mar 2024 (T+90)
9,933 shares@ US$5.950.0% of flowCommon StockSEC:0001437749-23-034041:0
66,021 shares@ US$9.340.2% of flowCommon StockSEC:0001437749-23-033920:0
Canonical exit: 4 Mar 2024 (T+90)
20,000 shares@ US$10.660.1% of flowCommon StockSEC:0001437749-23-033803:0
45,600 shares@ US$9.070.2% of flowCommon StockSEC:0001437749-23-033705:0
Canonical exit: 29 Feb 2024 (T+90)
152,944 shares@ US$9.060.5% of flowCommon StockSEC:0001437749-23-033556:0
Canonical exit: 28 Feb 2024 (T+90)
1,667 shares@ US$5.950.0% of flowCommon StockSEC:0001437749-23-033434:0
124,397 shares@ US$8.980.4% of flowCommon StockSEC:0001437749-23-033276:0
Canonical exit: 26 Feb 2024 (T+90)
241 shares@ US$6.100.0% of flowCommon StockSEC:0001437749-23-032670:0
Canonical exit: 15 Feb 2024 (T+90)
25 of 38 declarations
About Duggan Robert W
DUGGAN ROBERT W is Directeur Général. He has 38 filings in total, and in the sampled recent filings from 2021-05-14 to 2026-06-04, the transactions are all acquisitions, with EUR 638810613 of buys and EUR 0 of sells. These recent filings concern Summit Therapeutics Inc. and Pulse Biosciences, INC.
